Convalescent plasma - Is it useful for treating SARS Co-V2 infection?

Area of Science:

• * Infectious Diseases
• * Immunology
• * Hematology

Background:

• * The COVID-19 pandemic caused by SARS-CoV-2 presents a global health challenge with no definitive treatment.
• * Standard care and symptomatic treatment are currently administered to patients, but novel therapeutic strategies are under investigation.
• * Convalescent plasma (CP) has shown promise in treating previous respiratory infections like SARS and MERS.

Purpose of the Study:

• * To review current guidelines for the use of convalescent plasma (CP) in treating COVID-19.
• * To compare the guidelines issued by various international agencies regarding CP administration.
• * To highlight the potential of CP as an adaptive immunotherapy for SARS-CoV-2 infection.

Main Methods:

• * Review of existing literature and guidelines from regulatory and health organizations worldwide.
• * Comparison of recommendations for CP use in COVID-19 patients.
• * Analysis of CP's mechanism of action as passive antibody therapy.

Main Results:

• * Convalescent plasma contains antibodies that neutralize SARS-CoV-2, decreasing viral replication.
• * CP is considered a form of passive antibody therapy, expected to provide protection through viral neutralization and immune mechanisms.
• * While promising, randomized controlled studies for CP in COVID-19 are currently lacking.

Conclusions:

• * Convalescent plasma is an investigational therapy for COVID-19, with regulatory bodies and health organizations issuing guidelines for its use.
• * International agencies like the USFDA and European Blood Safety have provided guidance on CP administration.
• * Further clinical trials are needed to establish the efficacy and safety of CP as a treatment for SARS-CoV-2 infection.